ALNY

Alnylam Pharmaceuticals' stock price has significantly declined, falling approximately 38.0% since early 2026 and 44.30% over the last 12 months. A key event was the Q2 2026 earnings report on July 30, 2026; while adjusted EPS beat estimates ($1.84 vs. $1.63), revenue of $1.29 billion missed the $1.32 billion forecast. Crucially, the company lowered its full-year 2026 sales guidance for its TTR products (Amvuttra and Onpattro) by $200 million due to normalizing second-line demand for Amvuttra, causing shares to drop over 25% in premarket trading. Additionally, the unexpected Phase 3 failure of a competing ATTR-CM drug, eplontersen, from AstraZeneca and Ionis in July 2026, raised investor concerns about the potency of Alnylam's next-generation ATTR therapy, nucresiran, further contributing to the stock's decline.